医学
内科学
发热性中性粒细胞减少症
中性粒细胞减少症
养生
化疗
肿瘤科
造血干细胞移植
移植
外科
作者
Akihiro Ohmoto,Shigeo Fuji
出处
期刊:Blood Reviews
[Elsevier]
日期:2021-03-01
卷期号:46: 100738-100738
被引量:9
标识
DOI:10.1016/j.blre.2020.100738
摘要
Various chemotherapy regimens are used to treat patients with diffuse large B-cell lymphoma (DLBCL). However, treatment-related toxicity with a focus on infectious disease has not been fully reviewed. Several phase 3 trials have demonstrated different rates of febrile neutropenia (FN) between regimens (e.g. dose-adjusted (DA) EPOCH-R vs. R-CHOP). With heterogeneous patient characteristics, a combination regimen of lenalidomide or ibrutinib with R-CHOP exhibited promising efficacy with moderate infectious toxicity. While R-bendamustine is feasible for patients who don't tolerate other forms of chemotherapy, clinical data indicate increased opportunistic infections under prolonged lymphopenia. The usefulness of prophylactic antibiotics/antifungal agents in DLBCL patients is controversial owing to shorter and less severe neutropenia than with the induction regimen for acute leukemia or hematopoietic stem-cell transplantation. Prophylactic granulocyte-colony stimulating factor is recommended for intensive regimens such as DA-EPOCH-R, R-DHAP, or R-ICE. Regardless of multiple studies about FN incidence, studies focusing on microbiologic events are limited, and further investigations are warranted.
科研通智能强力驱动
Strongly Powered by AbleSci AI